Global Passive Transdermal Drug Delivery Market Research Report
- Report Code: PA 1000
- Publish Date: Upcoming
The global passive transdermal drug delivery market, mainly driven by ‘patent cliffs’, increased incidence of chronic diseases, increasing competition, improving patient compliance, reformulation and repositioning of drugs using advanced oral delivery systems, and huge investments made by big pharmaceutical companies, was valued at $12.27 billion in 2013 and is expected to reach $20.59 billion by 2018, at a CAGR of 10.9% from 2013 to 2018.
The U.S. is the world’s largest pharmaceuticals market. It is the world leader in biopharmaceutical research, with approximately 80% of the world’s research & development in biotechnology being conducted by U.S.-based firms. According to the Bureau of Labor Statistics, U.S.A, the pharmaceutical sector employed approximately 272,000 people, and spent $67.4 billion on research & development in 2010. Thus, the well-established pharmaceutical industry in the U.S. is a favorable factor for the growth of the drug delivery market.
The key drivers for the drug delivery market in North America are the robust pharmaceutical industry, large number of pharmaceutical companies and drug delivery technology providers, and the increasing number of collaborations and partnerships between technology providers and pharmaceutical companies. In addition, the growing demand for self-administration and home healthcare devices, along with the increasing applications of inhalers, transdermal patches, and transmucosal systems for chronic disease areas, such as migraine, diabetes, cancer pain, and asthma, has boosted the growth of the market in recent years. Healthcare reforms in the U.S. are expected to have significant impacts on the drug delivery market in the region.
Europe holds the second position, in terms of value, of the overall pharmaceutical market. The European pharmaceutical market was worth $228 billion in 2011, accounting for 26.8% of the global pharmaceuticals market. The industry invested $36.1 billion in R&D in 2011, provided direct employment to 660,000 Europeans, and generated three to four times more employment indirectly. However, the pharmaceutical markets in the major five European countries, namely Germany, France, the U.K., Italy, and Spain, grew at an average rate of 2.6% in 2011, due to the overall slow economic conditions in the region and the increasing competition from emerging nations.
The pharmaceutical markets in India and China are growing rapidly owing to low costs and favorable regulatory environments. The Indian pharmaceutical market was ranked 4th, in terms of volume, and 15th, in terms of value, in 2011, and is expected to reach $20 billion by 2015. The Chinese pharmaceutical market was ranked third-largest (by value), with size worth $64 billion, and is expected to become the second-largest by 2015, at a CAGR of 20% during the forecast period.
Asia held a share of 15.0% of the total drug delivery market in 2012 and was worth $21.71 billion. It is projected to grow at a CAGR of 12.6%, to reach $39.35 billion by 2017. The major factors propelling the Asian market are the saturated Western markets and aftermaths of the economic downturn in the U.S. and Europe. Furthermore, expansion of the Asian economy, increase in disposable incomes, development of healthcare infrastructure, increasing penetration of health insurance, and rising prevalence of chronic diseases are expected to drive the growth of the pharmaceutical market in the region. This, in turn, will accelerate the growth of the drug delivery market in Asia.
The report also provides an extensive competitive landscaping of the leading companies operating in the market. The main companies in the market include Novartis, Johnson & Johnson, 3M Company, and Noven, among others. Furthermore, segment and country-specific company shares, news & deals, M&A, segment-specific pipeline products, product approvals, and product recalls of the major companies have been detailed in this report.
Customization Options:
Along with the market data, customize the MMM assessments to meet your company’s specific needs. Customize to get a comprehensive summary of the industry standards and deep dive analysis of the following parameters:
Product Analysis
- Usage pattern (in-depth trend analysis) of products (segment-wise)
- Product matrix, which gives a detailed comparison of product portfolio of each company, mapped at country and sub-segment levels
- End-user adoption rate analysis of the products (segment-wise and country-wise)
- A comprehensive coverage of product approvals, pipeline products, and product recalls
Pharmacists Forum
- Fast turn-around analysis of pharmacists’ responses to market events and trends
- Pharmacists’ opinions about passive transdermal drug delivery products from different companies
- Pharmacists’ qualitative inputs on epidemiology data
- Pattern analysis of usage of drugs by physicians
Brand/Product Perception Matrix
- A comprehensive study of customers’ perception and behavior through our inbuilt social connect tool checking the virality and tonality of blogs
- An analysis of overall brand usage and familiarity and brand advocacy distribution (detractor/neutral/familiar)
Please fill in the form below to receive a free copy of the Summary of this Report
Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
| PRODUCT TITLE | PUBLISHED | |
|---|---|---|
|
|
Matrix System Matrix System and Reservoir System adds up to total Passive market.... |
Upcoming |
|
|
Reservoir System Reservoir System and Matrix System adds up to total Passive market.... |
Upcoming |
|
|
North American Passive Transdermal Drug Delivery Market The North American Passive Transdermal Drug Delivery Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance, and reformulation and repositioning of drugs, huge investment made by big pharmaceutical companies.The Market was Valued at $6.85 billion in 2013 and expected to be $11.33 billion by 2018, growing at a CAGR of 10.6 %. The Transdermal Drug Delivery Market analyzes the market by segments such as Active Transdermal Drug Delivery, and Passive Transdermal Drug Delivery. The prominent players in this Market are Novartis, Johnson & Johnson, 3M Company, Noven. |
Upcoming |
|
|
European Passive Transdermal Drug Delivery Market The European Passive Transdermal Drug Delivery Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance, and reformulation and repositioning of drugs, huge investment made by big pharmaceutical companies.The Market was Valued at $3.27 billion in 2013 and expected to be $5.19 billion by 2018, growing at a CAGR of 9.6 %. The Transdermal Drug Delivery Market analyzes the market by segments such as Active Transdermal Drug Delivery, and Passive Transdermal Drug Delivery. The prominent players in this Market are Novartis, Johnson & Johnson, 3M Company, Noven. |
Upcoming |
|
|
Asian Passive Transdermal Drug Delivery Market The Asian Passive Transdermal Drug Delivery Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance, and reformulation and repositioning of drugs, huge investment made by big pharmaceutical companies.The Market was Valued at $1.40 billion in 2013 and expected to be $2.82 billion by 2018, growing at a CAGR of 15.0%. The Transdermal Drug Delivery Market analyzes the market by segments such as Active Transdermal Drug Delivery, and Passive Transdermal Drug Delivery. The prominent players in this Market are Novartis, Johnson & Johnson, 3M Company, Noven. |
Upcoming |
